Kalvista Pharmaceuticals Limited operates as a limited liability company registered under Reg: 07543947 and created on February 25th, 2011, with a current status of active. The company’s headquarters are located at Porton Science Park in Porton Down, Surrey, SP4 0BF, UK. Kalvista specializes in the research, development, and commercialization of innovative oral medicines targeting hereditary angioedema (HAE) and related conditions. Their primary focus is on identifying novel therapeutic targets within this complex genetic disorder, aiming to deliver effective treatments with improved safety profiles. The company’s strategic approach centers around leveraging proprietary technologies and a robust pipeline of preclinical candidates. Kalvista’s services include clinical trial design, drug discovery, formulation development, and regulatory submissions for pharmaceutical products. The company is currently focusing on the advancement of HAE therapies through targeted gene editing approaches, with an emphasis on enhancing patient outcomes. They are actively pursuing international partnerships to expand market access and accelerate product development globally. As a Skilled Worker visa holder, Kalvista employs approximately 50 individuals across its research and development teams. The company’s international presence is demonstrated by strategic collaborations with pharmaceutical partners in North America and Europe.

Kalvista Pharmaceuticals Limited operates as a limited liability company registered under Reg: 07543947 and created on February 25th, 2011, with a current status of active. The company’s headquarters are located at Porton Science Park in Porton Down, Surrey, SP4 0BF, UK. Kalvista specializes in the research, development, and commercialization of innovative oral medicines targeting hereditary angioedema (HAE) and related conditions. Their primary focus is on identifying novel therapeutic targets within this complex genetic disorder, aiming to deliver effective treatments with improved safety profiles. The company’s strategic approach centers around leveraging proprietary technologies and a robust pipeline of preclinical candidates. Kalvista’s services include clinical trial design, drug discovery, formulation development, and regulatory submissions for pharmaceutical products. The company is currently focusing on the advancement of HAE therapies through targeted gene editing approaches, with an emphasis on enhancing patient outcomes. They are actively pursuing international partnerships to expand market access and accelerate product development globally. As a Skilled Worker visa holder, Kalvista employs approximately 50 individuals across its research and development teams. The company’s international presence is demonstrated by strategic collaborations with pharmaceutical partners in North America and Europe.